This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Axlr, Satt Du Languedoc Roussillon, Centre National De La Recherche Scientifique, Universitè De Montpellier. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2 
1 out of 5,383 
1 out of 297 
Years Active: 2020
Title: Pierre Cuq: Innovator in Cancer Treatment
Introduction
Pierre Cuq is an accomplished inventor based in Maurin, France, recognized for his contributions to the field of pharmaceuticals, particularly in cancer treatment. With a focus on innovative chemical compounds, Cuq has secured his place in the world of scientific research through his dedication and creativity.
Latest Patents
Pierre Cuq holds one notable patent titled “Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer.” This invention revolves around imidazo[1,2-a]quinoxaline compounds, designed specifically to combat cancer. The patent encompasses the chemical formula (I), pharmaceutical formulations containing these compounds, and their therapeutic applications in cancer treatment. This innovation highlights Cuq's commitment to developing effective solutions for one of society's most pressing health challenges.
Career Highlights
Throughout his career, Pierre Cuq has been affiliated with renowned institutions such as the University of Montpellier and the Centre National de la Recherche Scientifique. His roles at these organizations have allowed him to collaborate with leading experts in the field, further enriching his research and its implications for medical advancements.
Collaborations
In his professional journey, Cuq has collaborated with scholars and scientists, including Carine Deleuze-Masquefa and Pierre-Antoine Bonnet. These partnerships have played a significant role in his research endeavors, fostering a collaborative spirit that is essential for innovation in scientific research.
Conclusion
Pierre Cuq stands as a notable figure in the realm of cancer research and innovation. His patent on imidazo[1,2-a]quinoxalines reflects a significant advancement in therapeutic options for cancer patients. Through his work at respected institutions and his collaboration with esteemed colleagues, Cuq continues to contribute to the scientific community, leaving an indelible mark on the field of pharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile